Prajna Guha

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 4

Top Topics

Combination Therapy

Induced Apoptosis

Top Venues

Journal for immunotherapy of cancer

Cancer gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Chandra C Ghosh, Lauren Cournoyer, Yujia Liu, Alizee Ballarin, Ilan B Layman, Jason LaPorte, Molly Morrissey, Kayla Fraser, Shriya Perati, Bryan F Cox, Evgeny Yakirevich, Diana O Treaba, Timothy D Murtha, Prajna Guha, Steven C Katz, Diwakar Davar
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases. Journal for immunotherapy of cancer 12 (7) (2024)
Chandra C Ghosh, Lauren Cournoyer, Yujia Liu, Alizee Ballarin, Ilan B Layman, Jason LaPorte, Molly Morrissey, Kayla Fraser, Shriya Perati, Bryan F Cox, Evgeny Yakirevich, Diana O Treaba, Timothy D Murtha, Prajna Guha, Steven C Katz, Diwakar Davar
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases. Journal for immunotherapy of cancer 12 (7) (2024)
Chandra C Ghosh, Lauren Cournoyer, Yujia Liu, Alizee Ballarin, Ilan B Layman, Jason LaPorte, Molly Morrissey, Kayla Fraser, Shriya Perati, Bryan F Cox, Evgeny Yakirevich, Diana O Treaba, Timothy D Murtha, Prajna Guha, Steven C Katz, Diwakar Davar
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases. Journal for immunotherapy of cancer 12 (7) (2024)
Chandra C Ghosh, Kara R Heatherton, Kyle P O' Connell, Ian S Alexander, Deborah A Greer, Jason LaPorte, Prajna Guha, Bryan F Cox, Steven C Katz
Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition. Cancer gene therapy (2022)